论文部分内容阅读
目的分析不同治疗途径对支气管哮喘患者的临床疗效。方法将96例慢性支气管哮喘患者按照自愿原则分成不会或者不愿使用吸入装置的(观察组)46例和常规使用吸入装置的(对照组)50例。观察组使用白三烯受体拮抗剂一孟鲁司特钠片和沙丁胺醇片剂治疗,对照组给予吸入型糖皮质激素氟替卡松和沙丁胺醇片治疗,比较两组治疗前后患者哮喘症状评分和肺功能状况。结果观察组第4周临床症状全部消失,与对照组比较,差异无统计学意义(P>0.05)。两组治疗前后FEVl占预计值的百分比差异均无统计学意义(P>0.05),观察组FEVl改善率为20.7%,对照组FEVl改善率为20.6%,两组比较差异无统计学意义(P>0.05)。结论孟鲁司特钠片和沙丁胺醇片剂是类固醇吸入剂以及其他联用类固醇的吸入剂的有效替代药物,这可能对80%以上使用吸入剂有障碍、因副作用不能使用吸入剂或不想服用类固醇激素的患者均有益。
Objective To analyze the clinical effects of different therapeutic approaches on patients with bronchial asthma. Methods Ninety - six patients with chronic bronchial asthma were divided into two groups according to the principle of voluntariness. They were divided into observation group (46 cases) and control group (50 cases) who were not or unwilling to use inhalation device. The observation group received leukotriene receptor antagonist montelukast sodium tablets and salbutamol tablets, while the control group received inhaled glucocorticoid fluticasone and salbutamol tablets. The scores of asthma symptoms and pulmonary function before and after treatment in both groups were compared . Results The symptoms of the observation group disappeared in the 4th week. There was no significant difference between the observation group and the control group (P> 0.05). There was no significant difference in the percentage of predicted FEV1 before and after treatment (P> 0.05). The improvement rate of FEV1 was 20.7% in the observation group and 20.6% in the control group, there was no significant difference between the two groups (P > 0.05). CONCLUSION Montelukast sodium tablets and salbutamol tablets are effective alternatives to steroid inhalers and other inhalants for combination steroids which may be detrimental to the use of inhalers in excess of 80%, inability to use inhalers or to avoid steroids due to side effects Hormone patients are beneficial.